{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:36:44Z","timestamp":1787024204229,"version":"build-2736575974"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4,15]]},"DOI":"10.2146\/ajhp160228","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T06:45:13Z","timestamp":1491547513000},"page":"563-567","source":"Crossref","is-referenced-by-count":29,"title":["Dinutuximab for maintenance therapy in pediatric neuroblastoma"],"prefix":"10.1093","volume":"74","author":[{"given":"Lauren","family":"McGinty","sequence":"first","affiliation":[{"name":"University of Wisconsin Health, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Kolesar","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Kentucky, Lexington, KY"},{"name":"Early Phase Clinical Trials Center, Markey Cancer Center, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041103212818900_b1-0740563","volume-title":"Cancer facts & figures 2016","author":"American Cancer Society","year":"2016"},{"key":"key\n\t\t\t\t2019041103212818900_b2-0740563","doi-asserted-by":"crossref","first-page":"16078","DOI":"10.1038\/nrdp.2016.78","article-title":"Neuroblastoma","volume":"2","author":"Matthay","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"key\n\t\t\t\t2019041103212818900_b3-0740563","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","article-title":"The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report","volume":"27","author":"Cohn","year":"2009","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041103212818900_b4-0740563","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2014.59.4648","article-title":"Advances in risk classification and treatment strategies for neuroblastoma","volume":"33","author":"Pinto","year":"2015","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041103212818900_b5-0740563","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJM199910143411601","article-title":"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid","volume":"341","author":"Matthay","year":"1999","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103212818900_b6-0740563","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.1994.12.12.2607","article-title":"Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age","volume":"12","author":"Kushner","year":"1994","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041103212818900_b7-0740563","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/pbc.20219","article-title":"High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group","volume":"44","author":"Pritchard","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"key\n\t\t\t\t2019041103212818900_b8-0740563","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(05)70291-6","article-title":"Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial","volume":"6","author":"Berthold","year":"2005","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t2019041103212818900_b9-0740563","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/sj.bmt.1701737","article-title":"Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution","volume":"23","author":"Hartmann","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t2019041103212818900_b10-0740563","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s11912-000-0104-y","article-title":"Differentiating agents in pediatric malignancies: retinoids in neuroblastoma","volume":"2","author":"Reynolds","year":"2000","journal-title":"Curr Oncol Rep"},{"key":"key\n\t\t\t\t2019041103212818900_b11-0740563","first-page":"5914","article-title":"Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients","volume":"44","author":"Schulz","year":"1984","journal-title":"Cancer Res"},{"key":"key\n\t\t\t\t2019041103212818900_b12-0740563","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0005-2760(94)90034-5","article-title":"Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord","volume":"1214","author":"Svennerholm","year":"1994","journal-title":"Biochim Biophys Acta"},{"key":"key\n\t\t\t\t2019041103212818900_b13-0740563","volume-title":"Unituxin (dinutuximab) prescribing information","year":"2015"},{"key":"key\n\t\t\t\t2019041103212818900_b14-0740563","first-page":"58","article-title":"Defective antibody-dependent tumour cell lysis by neutrophils from cancer patients","volume":"77","author":"Dallegri","year":"1989","journal-title":"Clin Exp Immunol"},{"key":"key\n\t\t\t\t2019041103212818900_b15-0740563","first-page":"362","article-title":"A mechanism for neutrophil-mediated lysis of human neuroblastoma cells","volume":"53","author":"Barker","year":"1993","journal-title":"Cancer Res"},{"key":"key\n\t\t\t\t2019041103212818900_b16-0740563","first-page":"1846","article-title":"Usefulness of a chimeric anti-GD2 (ch14.18) and GM-CSF for refractory neuroblastoma","volume":"6","author":"Yu","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"key\n\t\t\t\t2019041103212818900_b17-0740563","first-page":"5234","article-title":"Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2","volume":"50","author":"Hank","year":"1990","journal-title":"Cancer Res"},{"key":"key\n\t\t\t\t2019041103212818900_b18-0740563","first-page":"1277","article-title":"Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients","volume":"3","author":"Albertini","year":"1997","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2019041103212818900_b19-0740563","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103212818900_b20-0740563","unstructured":"ClinicalTrials.gov. Monoclonal antibody ch14.18, sargramostim, aldesleukin, and isotretinoin after autologous stem cell transplant in treating patients with neuroblastoma(updated February 1, 2017). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01041638?term=NCT01041638&rank=1 (accessed 2015 Feb 10)."},{"key":"key\n\t\t\t\t2019041103212818900_b21-0740563","volume-title":"Lexicomp Online [online database]","author":"Dinutuximab [monograph]"},{"key":"key\n\t\t\t\t2019041103212818900_b22-0740563","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/pbc.25891","article-title":"When life expectancy is not short enough: a perspective on the National Institute for Health and Care Excellence (NICE) preliminary guidance for dinutuximab","volume":"63","author":"Adamson","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"key\n\t\t\t\t2019041103212818900_b23-0740563","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1001\/jama.2015.11845","article-title":"Experience with the priority review voucher program for drug development","volume":"314","author":"Kesselheim","year":"2015","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041103212818900_b24-0740563","doi-asserted-by":"crossref","first-page":"e0140002","DOI":"10.1371\/journal.pone.0140002","article-title":"Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries","volume":"10","author":"Gammie","year":"2015","journal-title":"PLoS One"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/74\/8\/563\/28337313\/ajhp0563.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T15:35:28Z","timestamp":1568993728000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/74\/8\/563\/5103381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,15]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,4,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp160228","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,4,15]]},"published":{"date-parts":[[2012,4,15]]}}}